HRS4R
Vull donar

JAVIER ABEL MENÉNDEZ MENÉNDEZ

Firma
JAVIER ABEL MENÉNDEZ-MENÉNDEZ
Posició
Cap de Grup - R4
Caps de Grup - R4

Projectes

Codi oficial: Pfizer 2019 Joaquim Bosch Data inici: 05/07/2019 Data fi: 30/06/2023 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: PFIZER, S.L.U. Ajuda: 97,750 €
Codi oficial: PID2019-104055GB-I00 Data inici: 01/06/2020 Data fi: 31/12/2023 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD MINECO / Ajuda: 242,000 €
Codi oficial: CP20/00003 Data inici: 01/01/2021 Data fi: 31/12/2025 Investigador/a principal: ELISABET CUYÀS NAVARRO Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 202,500 €
Codi oficial: CM22/00276 Data inici: 01/01/2023 Data fi: 31/12/2024 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 65,000 €
Codi oficial: VL93FSWZV Data inici: 01/01/2023 Data fi: 31/12/2024 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 24,000 €

Publicacions

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Espinoza I, Yang L, Steen TV, Vellon L, Cuyàs E, Verdura S, Lau L, Menendez JA, Lupu R

Binding of the angiogenic/senescence inducer CCN1/CYR61 to integrin alpha(6)beta(1) drives endocrine resistance in breast cancer cells

Aging-Us, 2022, 14, 1200-1213 dx.doi.org/10.18632/aging.203882
0

Fatty acid synthase: a druggable driver of breast cancer brain metastasis

EXPERT OPINION ON THERAPEUTIC TARGETS, 2022, 26, 427-444 dx.doi.org/10.1080/14728222.2022.2077189
0

Nuclear moonlighting of the secreted growth factor heregulin drives endocrine-resistant breast cancer independently of HER2/HER3 signaling

AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12, 2173-2188
0

Metformin and breast cancer: an opportunity for pharmacogenetics

Aging-Us, 2022, 14, 5612-5613 dx.doi.org/10.18632/aging.204180
0

Laparoscopic Sleeve Gastrectomy in Patients with Severe Obesity Restores Adaptive Responses Leading to Nonalcoholic Steatohepatitis

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23147830
0

Nutritional Niches of Cancer Therapy-Induced Senescent Cells

Nutrients, 2022, 14 dx.doi.org/10.3390/nu14173636
0

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986
0

Optimization of a GC-MS Injection-Port Derivatization Methodology to Enhance Metabolomics Analysis Throughput in Biological Samples

JOURNAL OF PROTEOME RESEARCH, 2022, 21, 2555-2565 dx.doi.org/10.1021/acs.jproteome.2c00119
0

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101

Formulari de contacte

Coneix l’IDIBGI!

menu